CSL Innovation Pty
CSL Innovation Pty is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Alpha-1 Antitrypsin for the Prevention of Graft-versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study was conducted in eight countries and enrolled 215 participants overall.
- The adolescent expansion cohort intended to enroll 5 to 10 participants, but only one adolescent was enrolled before study termination.
- The population was expanded in December 2024 to include matched related donors to enhance enrollment rates.
- Planned haploidentical donors and planned abatacept prophylaxis were excluded to maintain population homogeneity and avoid impact on the primary efficacy analysis.
- Home-health visits were added as an alternative to some in-clinic treatment-phase visits at some sites to reduce participant burden.
These findings describe the trial, not the service provider’s performance or responsibility.
Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
Sponsor CSL Behring LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for CSL Innovation Pty?
The 2026-10-09 snapshot links CSL Innovation Pty to 4 distinct CTIS trials. Recorded services include Laboratory services, Biomarker Testing, Measurement of exploratory biomarkers, PK/Immuno/Biomarker (Transcriptomoics) long term storage– leftover samples from consenting subjects will be used for future research testing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for CSL Innovation Pty?
The most frequently recorded therapeutic areas are Blood Disorders, Genetic and Congenital Disorders, Haematological Malignancies, Hepatology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to CSL Innovation Pty conducted?
The linked trials record locations in 11 countries, including Italy, Germany, Spain, Belgium, France. These are trial locations, not confirmed office locations or countries where CSL Innovation Pty delivered services.
What can this page tell me about CSL Innovation Pty's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under CSL Innovation Pty. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- CSL Innovation Pty Limited